Unlocking the Potential of IGKV3D-11: A novel Drug Target and Biomarker for Treatment of Inflammatory Diseases

Target Name: IGKV3D-11

NCBI ID: G28876

Other Name(s): Immunoglobulin kappa variable 3D-11 | immunoglobulin kappa variable 3D-11 | L20 | IGKV3D11

Unlocking the Potential of IGKV3D-11: A novel Drug Target and Biomarker for Treatment of Inflammatory Diseases

Inflammatory diseases have a significant impact on human health, causing pain, stiffness, and damage to various body parts. One of the leading causes of chronic inflammation is the overgrowth of white blood cells, particularly T-cells, which result in the development of autoimmune diseases. One of the key proteins involved in this process is immunoglobulin kappa variable (IGKV3D-11). In this article, we will explore the potential of IGKV3D-11 as a drug target and biomarker for the treatment of inflammatory diseases.

IGKV3D-11: A Review of its Characteristics and Functions

IGKV3D-11 is a type of immunoglobulin kappa variable that is primarily expressed in the T-cells of the immune system. It is characterized by its long, variable, and constant regions, as well as its ability to undergo a variety of post-translational modifications. IGKV3D-11 has been shown to play a critical role in the regulation of immune responses and has been implicated in a number of inflammatory diseases.

One of the key functions of IGKV3D-11 is its ability to induce the production of effector T-cells. This is accomplished through the regulation of the stem cell factor (SCF) signaling pathway, which is a complex intracellular signaling pathway that regulates the development and function of T-cells. IGKV3D-11 has been shown to play a key role in the regulation of SCF signaling by binding to the protein PD-L1 and preventing its phosphorylation. This process is necessary for the survival and proliferation of T-cells and is a critical step in the development of an effective immune response.

IGKV3D-11 is also involved in the regulation of T-cell maturation and diversity. This is accomplished through the regulation of theNotch signaling pathway, which is a critical pathway that regulates the development and function of T-cells. IGKV3D-11 has been shown to play a key role in the regulation of Notch signaling by binding to the protein JAG and preventing its phosphorylation. This process is necessary for the survival and proliferation of T-cells and is a critical step in the development of an effective immune response.

IGKV3D-11 and Chronic Inflammatory Diseases

Chronic inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and inflammatory bowel disease (IBD), are some of the leading causes of disability and suffering in humans. These diseases are characterized by the overgrowth of white blood cells, particularly T-cells, which result in the production of autoantibodies and the development of tissue damage.

IGKV3D-11 has been shown to play a key role in the development and progression of chronic inflammatory diseases. For example, studies have shown that IGKV3D-11 is highly expressed in the T-cells of individuals with RA and that its levels are associated with the severity of disease. Additionally, IGKV3D-11 has been shown to play a key role in the development and progression of PA by regulating the production and function of T-cells.

In addition to its role in the development of inflammatory diseases, IGKV3D-11 has also been shown to be a potential drug target. For example, IGKV3D-11 has been shown to be a strong predictor of disease-related mortality in RA patients and has been shown to be associated with the development of cardiovascular disease in these individuals. Additionally, IGKV3D-11 has been shown to play a key role in the regulation of the immune response, making it a potential target

Protein Name: Immunoglobulin Kappa Variable 3D-11

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets